Invitrogen Integrates

After a rough 2006 in which it struggled to integrate its acquisitions, Invitrogen (Nasdaq: IVGN  ) used last year to show why it made all of its purchases.

In 2007, the company managed to increase operating margins by 1% year over year and spat out $245 million in free cash flow. That's a 53% year-over-year increase in free cash flow per share.

It's an interesting dynamic for the laboratory supply companies. While almost every large drug company -- from Amgen (Nasdaq: AMGN  ) to Pfizer (NYSE: PFE  ) -- reported cost-cutting savings in 2007, laboratory supply companies like Invitrogen and Thermo Fisher Scientific (NYSE: TMO  ) saw decent growth in 2007. The cutbacks clearly aren't coming from basic research, which is a good sign for the future of both industries.

Invitrogen isn't done acquiring companies, either. In fact, it used some of the cash it earned in 2007 to acquire CellzDirect. The purchase helps Invitrogen continue its push into providing specialized cells for scientists, which I think is a good move for the company. Compared to companies like Becton Dickinson (NYSE: BDX  ) and Sigma-Aldrich (Nasdaq: SIAL  ) , Invitrogen is well poised to give scientists a complete package for their cell culture needs. And that's important, because there are few things that scientists dread more than having to spend time away from the laboratory bench ordering from three or four companies.

Separately from Tuesday's earnings announcement, Invitrogen also announced that it had settled multiple patent lawsuits with Agilent Technologies (NYSE: A  ) , which had been pending for about eight years. Payments and royalties are headed in both directions for different products that the two companies sell, but the companies didn't disclose financial details, so it's difficult to say who came out ahead.

With the patent lawsuits out of the way, Invitrogen is free to get back to increasing efficiencies. For 2008, the company is guiding for mid-single-digit revenue increases, with adjusted earnings per share expected to grow faster in the high-single to low-double digits. If it can continue to increase operating margins, investors should continue to be rewarded for patiently waiting for the integrations to occur.

More Foolishness:

Read/Post Comments (0) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 573017, ~/Articles/ArticleHandler.aspx, 10/28/2016 6:22:59 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 9 hours ago Sponsored by:
DOW 18,169.68 -29.65 -0.16%
S&P 500 2,133.04 -6.39 -0.30%
NASD 5,215.97 -34.29 -0.65%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

11/21/2008 4:00 PM
IVGN $22.23 Down +0.00 +0.00%
Invitrogen CAPS Rating: ****
A $43.38 Up +0.01 +0.02%
Agilent Technologi… CAPS Rating: ***
AMGN $160.57 Up +1.58 +0.99%
Amgen CAPS Rating: ****
BDX $167.25 Down -0.30 -0.18%
Becton Dickinson CAPS Rating: ****
PFE $32.48 Up +0.08 +0.25%
Pfizer CAPS Rating: ****
SIAL.DL $0.00 Down +0.00 +0.00%
Sigma-Aldrich CAPS Rating: *****
TMO $149.22 Up +1.18 +0.80%
Thermo Fisher Scie… CAPS Rating: ****